Harvard Bioscience Inc

Harvard Bioscience operates with a market capitalization of $24.9 million and a price-to-book ratio of 1.81, indicating a moderate premium to its book value. The company's liquidity position is characterized by $8.6 million in cash and equivalents, but this is offset by $35.9 million in long-term debt, resulting in a negative net cash position. The debt-to-equity ratio of 2.61 suggests a leveraged capital structure, and the current ratio of 2.2 indicates adequate short-term liquidity to cover obligations. Profitability metrics reveal a challenging operating environment for the company. The return on equity (ROE) is -4.13, and the return on assets (ROA) is -0.71, both significantly below the industry median for Advanced Medical Equipment & Technology. The company reported a net loss of $56.7 million, with an operating loss of $49.8 million, indicating a substantial decline in profitability compared to industry peers. Geographically and segment-wise, the company's revenue is concentrated in a single business line, as disclosed in its financial reporting. There is no public breakdown of revenue by geographic region or product segment, which limits visibility into diversification and exposure to regional economic conditions. Looking ahead, the company's revenue is expected to remain under pressure. The current fiscal year outlook shows a continuation of the operating loss trend, with no clear path to profitability in the next fiscal year. The free cash flow of -$52.6 million highlights the company's inability to generate positive cash from operations after capital expenditures. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, and while there is no immediate dilution pressure, the capital structure remains vulnerable to further debt financing. No recent dilutive events have been disclosed, and the company has not issued additional shares in the last reporting period. Recent filings and transcripts do not indicate any material events that would significantly alter the company's trajectory. The company's financial performance remains consistent with its recent history, and there are no new strategic initiatives or product launches disclosed in the latest available data.